Nausheen Ahmed: My takeaways on monitoring post infusion, REMS, CRS, ICANS and infection
Nausheen Ahmed, Medical Director of BMT Survivorship Program at The University of Kansas, shared a post on X by Heme Today adding:
“CART toxicity monitoring.
My takeaways based on findings from the Blood Advances publication on monitoring post infusion , REMS, CRS, ICANS and infection. There has to be a continuum in care with close partnership of community oncologists. There is no magic to the ‘4-week’ timepoint for non relapse mortality..
Quoting Heme Today’s post below:
“Nausheen Ahmed of The University of Kansas Health System spoke with Heme Today about current monitoring for side effects following CART therapy — Care providers must account for pts’ mortality risk not only from CRS or ICANS but also infection.”
Sources: Nausheen Ahmed/X and Heme Today/X